Evidence map›Paper›PMID 30314362›Full record

ReviewCancers2018

Cancer-Associated Thrombosis: An Overview of Mechanisms, Risk Factors, and Treatment.

Norbaini Binti Abdol Razak, Gabrielle Jones, Mayank Bhandari, Michael C Berndt, Pat Metharom

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cancers, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 320 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
320citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

320 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. [Development and validation of nomogram for predicting prognosis of patients with laryngeal squamous cell carcinoma after surgery].Lin chuang er bi yan hou tou jing wai ke za zhi = Journal of clinical otorhinolaryngology head and neck surgery · 2022
    Trial
  6. Trial
  7. Article
  8. Article
  9. Platelet subpopulations and contribution to hemostasis.Blood science (Baltimore, Md.) · 2026
    Review
  10. Article
  11. Article
  12. Observational
  13. Central venous access device-associated complication costs in paediatric cancer care.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026
    Observational
  14. Thrombin generation profiling in multiple myeloma: a comprehensive evaluation of prothrombotic state.Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis · 2026
    Article
  15. Article
  16. Review
  17. Review
  18. Article
  19. Review
  20. Review

260 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Norbaini Binti Abdol RazakSchool of Pharmacy and Biomedical Sciences, Curtin University, Perth 6100, Australia. n.abdolrazak@postgrad.curtin.edu.au.
Gabrielle JonesSchool of Pharmacy and Biomedical Sciences, Curtin University, Perth 6100, Australia. gabrielle.jones@postgrad.curtin.edu.au.
Mayank BhandariFiona Stanley Hospital, Perth 6150, Australia. Mayank.Bhandari@health.wa.gov.au.
Michael C BerndtSchool of Medicine, Curtin University, Perth 6100, Australia. m.berndt@curtin.edu.au.
Pat MetharomSchool of Pharmacy and Biomedical Sciences, Curtin University, Perth 6100, Australia. pat.metharom@curtin.edu.au.ORCID 0000-0003-2984-8796

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cancer-associated thrombosis is a major cause of mortality in cancer patients, the most common type being venous thromboembolism (VTE). Several risk factors for developing VTE also coexist with cancer patients, such as chemotherapy and immobilisation, contributing to the increased risk cancer patients have of developing VTE compared with non-cancer patients. Cancer cells are capable of activating the coagulation cascade and other prothrombotic properties of host cells, and many anticancer treatments themselves are being described as additional mechanisms for promoting VTE. This review will give an overview of the main thrombotic complications in cancer patients and outline the risk factors for cancer patients developing cancer-associated thrombosis, focusing on VTE as it is the most common complication observed in cancer patients. The multiple mechanisms involved in cancer-associated thrombosis, including the role of anticancer drugs, and a brief outline of the current treatment for cancer-associated thrombosis will also be discussed.

Indexed as

cancerthrombosisvenous thromboembolism

Identifiers

PMID30314362
PMCPMC6209883

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.